GLP1R and diabetes mellitus: In addition, these drugs have shown beneficial effects concerning cardiovascular disease (CVD) prevention in T2DM in recent clinical trials; thus, in the 2023 European Society of Cardiology (ESC) guidelines for the management of CVDs in patients with diabetes, GLP-1 RA are indicated as the first-choice treatment for T2DM patients at a high/very high CV risk or those with proven atherosclerotic CVD [69].